Cover Image
市場調查報告書

人類乳突病毒(HPV)相關的癌症:開發中產品分析

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 255958
出版日期 內容資訊 英文 265 Pages
訂單完成後即時交付
價格
Back to Top
人類乳突病毒(HPV)相關的癌症:開發中產品分析 Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2018
出版日期: 2018年04月30日 內容資訊: 英文 265 Pages
簡介

人類乳突病毒(HPV)是生殖器官最常見的病毒感染。已知人類乳突病毒(HPV)與數種類型的癌症相關。危險因素包括吸煙,免疫系統衰弱,長期口服避孕藥和慢性炎症等。人類乳突病毒(HPV)相關癌症由於症狀出現得極晚,一般症狀出現時已是末期,治療非常困難。

本報告提供全球人類乳突病毒(HPV)相關的癌症治療藥之開發趨勢調查,提供開發中產品的各開發階段比較分析,藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,該部門的最新趨勢,主要企業的檢討等資訊。

簡介

  • 調查範圍

HPV相關的癌症概要

治療藥的開發

  • 開發中產品;概要
  • 各企業的治療藥
  • 各大學/機關的治療藥
  • 企業開發中的產品
  • 大學/機關研究中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Abion Inc
  • Admedus Ltd
  • Advaxis Inc
  • Antigen Express Inc
  • Atara Biotherapeutics Inc
  • BioNTech AG
  • Cancer Research Technology Ltd
  • Cell Medica Ltd
  • Etubics Corp
  • EyeGene Inc
  • Formune SL
  • Genexine Inc
  • Hookipa Biotech AG
  • iBio Inc
  • Immunovaccine Inc
  • Inovio Pharmaceuticals Inc
  • ISA Pharmaceuticals BV
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Karyopharm Therapeutics Inc
  • Kite Pharma Inc
  • Lion Biotechnologies Inc
  • MedImmune LLC
  • Millennium Pharmaceuticals Inc
  • NeoImmuneTech Inc
  • Onconova Therapeutics Inc
  • Oryx GmbH & Co KG
  • PDS Biotechnology Corp
  • Peregrine Pharmaceuticals Inc
  • Profectus BioSciences Inc
  • Rottapharm Biotech Srl
  • Selecta Biosciences Inc
  • Shantha Biotechnics Ltd
  • Shuttle Pharmaceuticals LLC
  • Sirnaomics Inc
  • Solon Eiendom ASA
  • Theravectys SA
  • THEVAX Genetics Vaccine USA Inc
  • Tomegavax Inc
  • Transgene SA
  • UbiVac LLC
  • Vaccibody AS
  • Vault Pharma Inc
  • Virometix AG
  • VLPbio

藥物簡介

暫停中的計劃

開發中止的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10366IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2018, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape.

Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use and chronic inflammation. Human papillomavirus (HPV) associated cancer have no symptoms until it is quite advanced, very serious and hard to treat.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 18, 12, 39, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 11 and 2 molecules, respectively.

Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Human Papillomavirus (HPV) Associated Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • Introduction 5
  • Human Papillomavirus (HPV) Associated Cancer - Overview 6
  • Human Papillomavirus (HPV) Associated Cancer - Therapeutics Development 7
  • Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 19
  • Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 27
  • Human Papillomavirus (HPV) Associated Cancer - Drug Profiles 49
  • Human Papillomavirus (HPV) Associated Cancer - Dormant Projects 241
  • Human Papillomavirus (HPV) Associated Cancer - Discontinued Products 243
  • Human Papillomavirus (HPV) Associated Cancer - Product Development Milestones 244
  • Appendix 255

List of Tables

  • Table 1: Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H1 2018
  • Table 2: Number of Products under Development by Companies, H1 2018
  • Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Table 6: Number of Products under Development by Universities/Institutes, H1 2018
  • Table 7: Products under Development by Companies, H1 2018
  • Table 8: Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 9: Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Table 10: Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Table 11: Products under Development by Universities/Institutes, H1 2018
  • Table 12: Number of Products by Stage and Target, H1 2018
  • Table 13: Number of Products by Stage and Mechanism of Action, H1 2018
  • Table 14: Number of Products by Stage and Route of Administration, H1 2018
  • Table 15: Number of Products by Stage and Molecule Type, H1 2018
  • Table 16: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Abion Inc, H1 2018
  • Table 17: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Abivax SA, H1 2018
  • Table 18: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Admedus Ltd, H1 2018
  • Table 19: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Advaxis Inc, H1 2018
  • Table 20: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Amgen Inc, H1 2018
  • Table 21: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Antigen Express Inc, H1 2018
  • Table 22: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2018
  • Table 23: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2018
  • Table 24: Human Papillomavirus (HPV) Associated Cancer - Pipeline by BioNTech AG, H1 2018
  • Table 25: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Research Technology Ltd, H1 2018
  • Table 26: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Denceptor Therapeutics Ltd, H1 2018
  • Table 27: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corp, H1 2018
  • Table 28: Human Papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene Inc, H1 2018
  • Table 29: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Formune SL, H1 2018
  • Table 30: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Genexine Inc, H1 2018
  • Table 31: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Hookipa Biotech AG, H1 2018
  • Table 32: Human Papillomavirus (HPV) Associated Cancer - Pipeline by iBio Inc, H1 2018
  • Table 33: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Immunovaccine Inc, H1 2018
  • Table 34: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals Inc, H1 2018
  • Table 35: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Iovance Biotherapeutics Inc, H1 2018
  • Table 36: Human Papillomavirus (HPV) Associated Cancer - Pipeline by ISA Pharmaceuticals BV, H1 2018
  • Table 37: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Johnson & Johnson, H1 2018
  • Table 38: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Juno Therapeutics Inc, H1 2018
  • Table 39: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2018
  • Table 40: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Kite Pharma Inc, H1 2018
  • Table 41: Human Papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune LLC, H1 2018
  • Table 42: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Merck KGaA, H1 2018
  • Table 43: Human Papillomavirus (HPV) Associated Cancer - Pipeline by NeoImmuneTech Inc, H1 2018
  • Table 44: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics Inc, H1 2018
  • Table 45: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Oxford Vacmedix UK Ltd, H1 2018
  • Table 46: Human Papillomavirus (HPV) Associated Cancer - Pipeline by PDS Biotechnology Corp, H1 2018
  • Table 47: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Profectus BioSciences Inc, H1 2018
  • Table 48: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Rottapharm Biotech Srl, H1 2018
  • Table 49: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Selecta Biosciences Inc, H1 2018
  • Table 50: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2018
  • Table 51: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shuttle Pharmaceuticals Inc, H1 2018
  • Table 52: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Sierra Oncology Inc, H1 2018
  • Table 53: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Sirnaomics Inc, H1 2018
  • Table 54: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Theravectys SA, H1 2018
  • Table 55: Human Papillomavirus (HPV) Associated Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H1 2018
  • Table 56: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Touchlight Genetics Ltd, H1 2018
  • Table 57: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Transgene SA, H1 2018
  • Table 58: Human Papillomavirus (HPV) Associated Cancer - Pipeline by UbiVac LLC, H1 2018
  • Table 59: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vaccibody AS, H1 2018
  • Table 60: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vault Pharma Inc, H1 2018
  • Table 61: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vectorite Biomedical Inc, H1 2018
  • Table 62: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Virometix AG, H1 2018
  • Table 63: Human Papillomavirus (HPV) Associated Cancer - Pipeline by VLPbio, H1 2018
  • Table 64: Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vyriad Inc, H1 2018
  • Table 65: Human Papillomavirus (HPV) Associated Cancer - Dormant Projects, H1 2018

List of Figures

  • Figure 1: Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H1 2018
  • Figure 2: Number of Products under Development by Companies, H1 2018
  • Figure 3: Number of Products under Development by Universities/Institutes, H1 2018
  • Figure 4: Number of Products by Top 10 Targets, H1 2018
  • Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018
  • Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Figure 10: Number of Products by Top 10 Molecule Types, H1 2018
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top